When AI Gives Off-Label Drug Advice: What Pharma Must Track Now
A patient asks ChatGPT whether their antidepressant can help with chronic pain. Another asks Gemini if a GLP-1 drug will […]
A patient asks ChatGPT whether their antidepressant can help with chronic pain. Another asks Gemini if a GLP-1 drug will […]
When a patient types “is Ozempic safe for someone with a history of pancreatitis?” into ChatGPT, they get an answer
A patient asks ChatGPT whether their antidepressant can help with chronic pain. Another asks Gemini if a GLP-1 drug will
Most pharmaceutical companies still don’t know what ChatGPT says about their drugs. They don’t know whether Perplexity recommends their biologic
At some point in the last eighteen months, the drug information environment crossed a threshold. Patients stopped asking Google first.
When a patient asks ChatGPT whether they can take Ozempic while on metformin, that answer — accurate or not —
When a patient types “can I take Ozempic with metformin” into ChatGPT, they are not reading an FDA-approved label. They
Amgen’s Hadlima launched in the United States in July 2023. AbbVie’s Humira had dominated adalimumab prescribing for two decades. The
Every day, millions of patients and physicians type drug questions into ChatGPT, Gemini, Perplexity, and Claude. They ask whether Ozempic
Drug safety surveillance has a new blind spot. Millions of patients are now asking ChatGPT, Gemini, Claude, and Perplexity about
A patient in Phoenix types ‘is Ozempic safe for someone with a history of pancreatitis?’ into ChatGPT at 11 p.m.
In late 2023, a patient with type 2 diabetes asked ChatGPT whether semaglutide could eliminate the need for insulin entirely.
Sign in or create a free account to read this DrugChatter article